跳至主要内容
临床试验/NCT01491659
NCT01491659撤回4 期

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect and Safety of Idoform Plus on Bowel Side Effects in Healthy Subjects Treated With Amoxicillin/ Clavulanate

Pfizer0 个研究点开始时间: 2013年1月最近更新:
适应症

试验速览

阶段
4 期
状态
撤回
发起方
Pfizer
主要终点
Occurence of Antibiotic Associated Diarrhea

研究概览

简要总结

It is hypothesized that Idoform plus will recuce the occurence of gastrointestinal side effects related to the use of antibiotics

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteers 18-70 years of age
  • Subjects with normal gastrointestinal function
  • Subjects willing to provide written informed consent

排除标准

  • Subjects receiving antibiotic treatment within three months prior to inclusion in the study
  • Pregnancy or planned pregnancy
  • Breast feeding
  • Subjects who are allergic to beta-lactam antibiotics, amoxicillin / clavulanate or its components
  • Subjects with known renal insufficiency
  • Subjects using products containing probiotics, fibers and/or prebiotics
  • Subjects using proton pump inhibitors
  • Subjects using H2 antagonists
  • Subjects using antacids frequently

结局指标

主要结局

Occurence of Antibiotic Associated Diarrhea

时间窗: 17 days

次要结局

  • Duration of Antibiotic Associated Diarrhoea(17 days)
  • Occurrence of Antibiotic Associated Loose Stools (Types 5,6 or 7 on the Bristol Stool Chart) at Least Once During a Day(17 days)
  • Presence of Gastrointestinal Symptoms (Abdominal Pain; Bloating/Distension; Nausea/Upset Stomach), and the Severity of Each Symptom(17 days)
  • Changes in the Gut Microbiota Composition(17 days)
  • Changes in Markers of Antibiotic Resistance(17 days)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

相似试验